Drug-drug interactions in the elderly

被引:150
|
作者
Björkman, IK [1 ]
Fastbom, J
Schmidt, IK
Bernsten, CB
机构
[1] Apoteket AB Swedish Natl Corp Pharm, Stockholm, Sweden
[2] Dept Publ Hlth & Caring Sci, Uppsala, Sweden
[3] Natl Board Hlth & Welf, Stockholm, Sweden
关键词
drug-drug interactions; elderly;
D O I
10.1345/aph.1A484
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To detect the frequency of potential drug-drug interactions (DDIs) in an outpatient group of elderly people in 6 European countries, as well as to describe differences among countries. DATA SOURCES AND METHODS: Drug use data were collected from 1601 elderly persons living in 6 European countries. The study population participated in a controlled intervention study over 18 months investigating the impact of pharmaceutical care. Potential DDIs were studied using a computerized detection program. RESULTS: The elderly population used on average 7.0 drugs per person; 46% had at least 1 drug combination possibly leading to a DDI. On average, there were 0.83 potential DDIs per person. Almost 10% of the potential DDIs were classified to be avoided according to the Swedish interaction classification system, but nearly one-third of them were to be avoided only for predisposed patients. The risk of subtherapeutic effect as a result of a potential DDI was as common as the risk of adverse reactions. Furthermore, we found differences in the frequency and type of potential DDIs among the countries. CONCLUSIONS: Potential DDIs are common in elderly people using many drugs and are part of a normal drug regimen. Some combinations are likely to have negative effects; more attention must be focused on detecting and monitoring patients using such combinations. As differences in potential DDIs among countries were found, the reasons for this variability need to be explored in further studies.
引用
收藏
页码:1675 / 1681
页数:7
相关论文
共 50 条
  • [41] Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients
    Forbes, Heather L.
    Polasek, Thomas M.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2017, 8 (10) : 319 - 328
  • [42] DRUG-DRUG INTERACTIONS AS AN ISSUE IN DRUG DEVELOPMENT
    Jochemsen, R.
    Bouzom, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 2 - 2
  • [43] Severe drug-drug interactions in elderly patients on medications frequently used in dermatology
    Bouteiller, J.
    Carvalho, P.
    Commin, M. -h.
    Massy, N.
    Tetart, F.
    Joly, P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2021, 148 (03): : 183 - 184
  • [44] Pharmacokinetic Drug-Drug Interactions and Herb-Drug Interactions
    Choi, Min-Koo
    Song, Im-Sook
    PHARMACEUTICS, 2021, 13 (05)
  • [45] DRUG UTILIZATION AND POTENTIAL DRUG-DRUG INTERACTIONS
    LAVENTURIER, MF
    TALLEY, RB
    HEFNER, DL
    KENNARD, LH
    JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1976, 16 (02): : 77 - 81
  • [46] Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study
    Obreli-Neto, Paulo Roque
    Nobili, Alessandro
    Baldoni, Andre de Oliveira
    Guidoni, Camilo Molino
    de Lyra Junior, Divaldo Pereira
    Pilger, Diogo
    Duzanski, Juliano
    Tettamanti, Mauro
    Cruciol-Souza, Joice Mara
    Gaeti, Walderez Penteado
    Nakamura Cuman, Roberto Kenji
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (12) : 1667 - 1676
  • [47] Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments
    Fokter, Nina
    Mozina, Martin
    Brvar, Miran
    WIENER KLINISCHE WOCHENSCHRIFT, 2010, 122 (3-4) : 81 - 88
  • [48] Potential Drug-Drug Interactions and Admissions Due to Drug-Drug Interactions in Patients Treated in Medical Departments
    Fokter, N.
    Mozina, M.
    Bone, M.
    Brvar, M.
    CLINICAL TOXICOLOGY, 2009, 47 (05) : 496 - 497
  • [49] DRUG-DRUG INTERACTION DATABASES: SENSITIVITY AND SPECIFICITY TO DETECT MANIFEST DRUG-DRUG INTERACTIONS, RELIABILITY RATINGS AND MANAGEMENT STRATEGIES OF POTENTIAL DRUG-DRUG INTERACTIONS
    Ocovska, Z.
    Marikova, M.
    Kukralova, K.
    Vlcek, J.
    VALUE IN HEALTH, 2022, 25 (01) : S140 - S141
  • [50] Drug-drug interactions are unlikely with ibandronate
    Bauss, F
    Kling, L
    Worth, E
    Barrett, J
    OSTEOPOROSIS INTERNATIONAL, 2004, 15 : S101 - S101